{"text": ["Novartis\u2019s", "Business", "Segments", "in", "Q2", "2018"], "created_at": "2018-08-28 19:25:02"}
{"text": ["Why", "Ionis", "Pharmaceuticals", "Stock", "Is", "Plummeting", "Today"], "created_at": "2018-08-28 18:12:48"}
{"text": ["Gilead's", "CAR-T", "Therapy", "Yescarta", "Gets", "Approval", "in", "Europe"], "created_at": "2018-08-28 17:57:29"}
{"text": ["Gilead's", "CAR-T", "Therapy", "Yescarta", "Gets", "Approval", "in", "Europe"], "created_at": "2018-08-28 17:57:29"}
{"text": ["Novartis\u2019s", "Quarterly", "Revenue", "Trend", "in", "Q2", "2018"], "created_at": "2018-08-28 17:55:02"}
{"text": ["Novartis\u2019s", "Valuation", "in", "August"], "created_at": "2018-08-28 16:20:35"}
{"text": ["The", "Swiss", "Stock", "Market", "Pulled", "Back", "As", "Defensive", "Heavyweights", "Fell"], "created_at": "2018-08-28 12:05:00"}
{"text": ["The", "Swiss", "Stock", "Market", "Pulled", "Back", "As", "Defensive", "Heavyweights", "Fell"], "created_at": "2018-08-28 12:05:00"}
{"text": ["Lucentis", "and", "Hemlibra", "Could", "Boost", "Roche\u2019s", "Revenue", "Growth"], "created_at": "2018-08-28 11:30:02"}
